icon-folder.gif   Conference Reports for NATAP  
 
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
 
 
 
A response-guided approach to pegylated interferon alpha-2a (40KD) therapyto improve response rates in HBeAg-negative, genotype D patients
 
 
  Reported by Jules Levin AASLD Nov 5-8 2011 SF
 
P. Lampertico,1 M. Vigan˛,1 G.G. Di Costanzo,2 E. Sagnelli,3 M. Fasano,4 V. Di Marco,5 S. Boninsegna,6 P. Farci,7 S. Fargion,1 T. Giuberti,8 V. Rothe,9 L. Regep,10 B. Massetto,11 F. Facchetti,1 M. Colombo1 on behalf of the PegBeLiver Study Group 11st Gastroenterology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, UniversitÓ degli Studi di Milano, Milan, Italy; 2Liver Unit, Cardarelli Hospital, Naples, Italy; 3Infectious Disease Unit, SS. Anna and Sebastiano Hospital, Caserta, Italy; 4Clinic of Infectious Diseases, UniversitÓ di Bari, Bari, Italy; 5Gastroenterology and Hepatology Unit, (Di.Bi.M.I.S.) University of Palermo, Palermo, Italy; 6Department of Surgical and Gastroenterological Sciences, University of Padua, Padua, Italy; 7Medical Science Department, University of Cagliari, Monserrato, Italy; 8Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero, University of Parma, Parma, Italy; 9IST GmbH, Mannheim, Germany; 10F. Hoffmann-La Roche, Basel, Switzerland; 11 formerly of Roche, Monza, Italy

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif